S. Shoaf

发表

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

A. Chapman, V. Torres, J. Ouyang, 2017, Journal of clinical pharmacology.

Neuroimaging in alcoholism: ethanol and brain damage.

R R Rawlings, R Momenan, G Mundle, 2001, Alcoholism, clinical and experimental research.

Maternal absence and stability of individual differences in CSF 5-HIAA concentrations in rhesus monkey infants.

M. Linnoila, M. Schwandt, C. Shannon, 2005, The American journal of psychiatry.

The Effect of Dietary Polyunsaturated Fatty Acids and Alcohol on Neurotransmitter Levels in Rat Brain.

S. Shoaf, N. Salem, N. U. Olsson, 1998, Nutritional neuroscience.

Population‐based meta‐analysis of hydrochlorothiazide pharmacokinetics

S. Shoaf, D. Mager, S. V. Van Wart, 2013, Biopharmaceutics & drug disposition.

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

S. Shoaf, S. Mallikaarjun, P. Bricmont, 2013, Kidney international.

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

S. Shoaf, S. Mallikaarjun, P. Bricmont, 2011, European Journal of Clinical Pharmacology.

Distribution of free and conjugated dopamine in rats and mice.

S. Shoaf, M. Elchisak, 1983, Life sciences.

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide

S. Shoaf, Christopher A. Zimmer, P. Bricmont, 2007, Journal of cardiovascular pharmacology.

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial

D. Mekahli, M. Cadnapaphornchai, S. Shoaf, 2019, European Journal of Pediatrics.

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

A. Chapman, R. Perrone, J. Ouyang, 2020, Kidney international reports.

A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.

J. Ouyang, O. Sergeyeva, S. Shoaf, 2020, Clinical journal of the American Society of Nephrology : CJASN.

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

S. Shoaf, S. Lanke, Shankar Lanke, 2019, Journal of clinical pharmacology.

Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults

S. Shoaf, P. Bricmont, Ann Dandurand, 2017, European Journal of Clinical Pharmacology.

The pharmacokinetics of S-(-)equol administered as SE5-OH tablets to healthy postmenopausal women.

S. Shoaf, K. Setchell, Xueheng Zhao, 2009, The Journal of nutrition.

Effects of Acute Metabolic Stress on the Peripheral Vasopressinergic System in Schizophrenia

C. Adler, S. Lukas, S. Shoaf, 2003, Journal of psychopharmacology.

Rapid changes in cytochrome P4502E1 (CYP2E1) activity and other P450 isozymes following ethanol withdrawal in rats.

S. Shoaf, B. J. Roberts, B. Song, 1995, Biochemical pharmacology.

Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

S. Shoaf, D. Mager, S. V. Van Wart, 2013, Biopharmaceutics & drug disposition.

Ethanol Induces CYP2E1 by Protein Stabilization

S. Shoaf, Y. Soh, B. Song, 1995, The Journal of Biological Chemistry.

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

P. Watkins, K. Brouwer, S. Shoaf, 2016, Toxicological sciences : an official journal of the Society of Toxicology.

Effects of Desipramine, Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy

R. Dubner, M. Max, S. Shoaf, 1993 .

Comparison of Two Doses and Dosing Regimens of Tolvaptan in Congestive Heart Failure

S. Shoaf, C. Orlandi, J. Udelson, 2005, Journal of cardiovascular pharmacology.

Clarification of Enrolled Subjects in Tolvaptan HF Trials

J. Blais, S. Shoaf, J. Chiodo, 2014, Clinical pharmacology and therapeutics.

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

S. Shoaf, S. Mallikaarjun, P. Bricmont, 2012, European Journal of Clinical Pharmacology.

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.

S. Shoaf, S. Mallikaarjun, P. Bricmont, 2012, British journal of clinical pharmacology.

Plasma total cholesterol concentrations do not predict cerebrospinal fluid neurotransmitter metabolites: implications for the biophysical role of highly unsaturated fatty acids.

M. Linnoila, S. Shoaf, J. Hibbeln, 2000, The American journal of clinical nutrition.

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters

S. Shoaf, P. Bricmont, Jennifer Repella Gordon, 2021, Clinical and translational science.

Ethanol Induces CYP2E1 by Protein Stabilization ROLE OF UBIQUITIN CONJUGATION IN THE RAPID DEGRADATION OF CYP2E1*

S. Shoaf, Y. Soh, B. Song, 1995 .

Cilostazol and Dipyridamole Synergistically Inhibit Human Platelet Aggregation

Yongge Liu, F. Czerwiec, S. Shoaf, 2004, Journal of cardiovascular pharmacology.

Salivary prolactin as a marker for central serotonin turnover

M. Linnoila, S. Lindell, S. Suomi, 1999, Biological Psychiatry.

Brain Serotonin Synthesis Rates in Rhesus Monkeys Determined by [11C;[alpha;-Methyl-L-Tryptophan and Positron Emission Tomography Compared to CSF 5-Hydroxyindole-3-Acetic Acid Concentrations

D. Hommer, P. Herscovitch, R. Carson, 1998, Neuropsychopharmacology.

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

R Dubner, R. Dubner, M. Max, 1992, The New England journal of medicine.

Serotonergic influences on life‐history outcomes in free‐ranging male rhesus macaques

S. Suomi, G. Westergaard, S. Shoaf, 2007, American journal of primatology.

Early experience and serotonin transporter gene variation interact to influence primate CNS function

K. Lesch, J. Long, A. Heils, 2002, Molecular Psychiatry.

Pharmacokinetics of trimethoprim/sulfadiazine in neonatal calves: influence of synovitis.

S. Shoaf, C. Guard, W. Schwark, 1986, Journal of veterinary pharmacology and therapeutics.

CSF monoamine metabolites and MRI brain volumes in alcohol dependence

Reza Momenan, Ingrid Agartz, D. Hommer, 2003, Psychiatry Research: Neuroimaging.

Chlorzoxazone metabolism is increased in fasted Sprague‐Dawley rats

S. Shoaf, B. Song, L. Ernstgård, 2006, The Journal of pharmacy and pharmacology.

Effects of Acute Tryptophan Depletion on Plasma and Cerebrospinal Fluid Tryptophan and 5‐Hydroxyindoleacetic Acid in Normal Volunteers

D Hommer, R Rawlings, M Linnoila, 1999, Journal of neurochemistry.

The development of hepatic drug-metabolizing enzyme activity in the neonatal calf and its effect on drug disposition.

S. Shoaf, C. Guard, J. Babish, 1987, Drug metabolism and disposition: the biological fate of chemicals.

Coadministration of fluvoxamine increases serum concentrations of haloperidol.

A. Abi-Dargham, D. Daniel, S. Shoaf, 1994, Journal of clinical psychopharmacology.

Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid.

S. Shoaf, C. Guard, W. Schwark, 1989, American journal of veterinary research.

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

A. Chapman, O. Devuyst, F. Czerwiec, 2017, Kidney international reports.

Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking.

M. Eckardt, M. Linnoila, S. Shoaf, 1999, Alcoholism, clinical and experimental research.

Seasonal Variation in CSF 5-HIAA Concentrations in Male Rhesus Macaques

M. Linnoila, S. Suomi, J. Higley, 2000, Neuropsychopharmacology.

Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole

S. Shoaf, D. Boulton, S. Mallikaarjun, 2008, Clinical pharmacokinetics.

Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias

S. Shoaf, C. Orlandi, L. Grinfeld, 2005, Journal of cardiovascular pharmacology and therapeutics.

Serotonin, testosterone and alcohol in the etiology of domestic violence

S. Shoaf, J. Umhau, D. George, 2001, Psychiatry Research.

A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids

M. Linnoila, S. Shoaf, J. Hibbeln, 1998, Biological Psychiatry.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

S. Bakker, R. Gansevoort, E. Meijer, 2013, Kidney international.

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects

S. Shoaf, S. Mallikaarjun, 2012, Clinical pharmacology in drug development.

In Vitro P‐Glycoprotein Interactions and Steady‐State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

S. Shoaf, M. Furukawa, E. Kashiyama, 2011, Journal of clinical pharmacology.

The effect of age and diet on sulfadiazine/trimethoprim disposition following oral and subcutaneous administration to calves.

S. Shoaf, C. Guard, W. Schwark, 1987, Journal of veterinary pharmacology and therapeutics.

Ondansetron modulates pharmacodynamic effects of ketamine on electrocardiographic signals in rhesus monkeys.

S. Suomi, S. Shoaf, P. DePetrillo, 2000, European journal of pharmacology.

Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders: An Open-Label, Dose-Escalation Study

R. Kauffman, F. Sallee, R. Findling, 2008, Journal of clinical psychopharmacology.

Population‐based meta‐analysis of furosemide pharmacokinetics

Donald E Mager, S. Shoaf, D. Mager, 2014, Biopharmaceutics & drug disposition.

Vascular reactivity in alcoholic rat aortas: in vitro interactions between catecholamines and alcohol.

S. Shoaf, B. Song, H. Rhee, 1995, Neurotoxicology.

Induction of CYP2E1 in liver, kidney, brain and intestine during chronic ethanol administration and withdrawal: evidence that CYP2E1 possesses a rapid phase half-life of 6 hours or less.

S. Shoaf, B. J. Roberts, B. Song, 1994, Biochemical and biophysical research communications.

Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications.

S. Shoaf, M. Linnoila, 1991, Psychopharmacology bulletin.

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD

A. Chapman, R. Perrone, J. Ouyang, 2020, Kidney international reports.

Effects of a single oral dose of desipramine on postoperative morphine analgesia.

M. Max, S. Shoaf, C. Buzzanell, 1992, Journal of pain and symptom management.

Pharmacokinetic data in the evaluation of the safety of food and color additives.

S. Shoaf, J. C. Griffiths, C. S. Lin, 1992, Regulatory toxicology and pharmacology : RTP.

Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease

M. Litwin, L. Guay-Woodford, D. Mekahli, 2023, Clinical journal of the American Society of Nephrology : CJASN.

The Suitability of [11C]-α-Methyl-L-tryptophan as a Tracer for Serotonin Synthesis: Studies With Dual Administration of [11C] and [14C] Labeled Tracer

Peter Herscovitch, William C. Eckelman, Wendol A. Williams, 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

S. Shoaf, S. Mallikaarjun, P. Bricmont, 2012, European Journal of Clinical Pharmacology.

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects.

S. Shoaf, S. Mallikaarjun, P. Bricmont, 2012, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single‐Dose Studies in Healthy Subjects

S. Shoaf, S. Mallikaarjun, P. Bricmont, 2007, Journal of clinical pharmacology.

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

S. Shoaf, L. Geiter, A. Paccaly, 2016, Antimicrobial Agents and Chemotherapy.

Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults

Yiyun Huang, R. Carson, N. Nabulsi, 2022, Journal of Psychopharmacology.

[α-11C]Methyl-l-tryptophan in Anesthetized Rhesus Monkeys

D. Hommer, P. Herscovitch, R. Carson, 2001 .

Inverse relationship between plasma epinephrine and testosterone levels during acute glucoprivation in healthy men.

C. Adler, S. Shoaf, I. Elman, 2001, Life sciences.

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

S. Shoaf, S. Mallikaarjun, P. Bricmont, 2012, European Journal of Clinical Pharmacology.

Population‐based meta‐analysis of hydrochlorothiazide pharmacokinetics

S. Shoaf, D. Mager, S. V. Van Wart, 2013, Biopharmaceutics & drug disposition.